Total submissions: 4
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Labcorp Genetics |
RCV001377305 | SCV001574606 | pathogenic | not provided | 2024-01-23 | criteria provided, single submitter | clinical testing | This sequence change affects a donor splice site in intron 11 of the CFI gene. It is expected to disrupt RNA splicing. Variants that disrupt the donor or acceptor splice site typically lead to a loss of protein function (PMID: 16199547), and loss-of-function variants in CFI are known to be pathogenic (PMID: 15917334, 16621965, 19065647, 20016463, 22710145). This variant is present in population databases (rs368555424, gnomAD 0.006%). Disruption of this splice site has been observed in individual(s) with CFI-related conditions (PMID: 23421077, 24036952, 28455885; Invitae). In at least one individual the data is consistent with being in trans (on the opposite chromosome) from a pathogenic variant. ClinVar contains an entry for this variant (Variation ID: 1066334). Algorithms developed to predict the effect of sequence changes on RNA splicing suggest that this variant may disrupt the consensus splice site. For these reasons, this variant has been classified as Pathogenic. |
Genome Diagnostics Laboratory, |
RCV002294457 | SCV002587656 | likely pathogenic | Atypical hemolytic-uremic syndrome | 2021-02-10 | criteria provided, single submitter | clinical testing | |
Fulgent Genetics, |
RCV002504628 | SCV002815539 | pathogenic | Atypical hemolytic-uremic syndrome with I factor anomaly; Age related macular degeneration 13; Factor I deficiency | 2022-05-16 | criteria provided, single submitter | clinical testing | |
Mayo Clinic Laboratories, |
RCV001377305 | SCV005413657 | pathogenic | not provided | 2023-09-26 | criteria provided, single submitter | clinical testing | PM2, PS3_supporting, PS4_moderate, PVS1 |